Zydus Lifesciences receives USFDA approval for Dapsone Gel 7.5%

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Dapsone Gel, 7.5%, (USRLD: Aczone Gel 7.5%).

Dapsone Gel is used to treat acne and will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India).

Dapsone Gel, 7.5% had annual sales of USD 35.8 mn in the United States (IQVIA MAT March 24).

Powered by Capital Market - Live News